Trial Profile
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2015
Price :
$35
*
At a glance
- Drugs XL 019 (Primary)
- Indications Polycythaemia vera
- Focus Adverse reactions
- Sponsors Exelixis
- 17 Sep 2014 New trial record